BUSINESSQUARTZ
Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
Biogen is acquiring RayThera for up to $1 billion, adding small-molecule anti-inflammatory drug candidates to its pipeline. The lead asset from RayThera is expected to begin human trials this summer.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Eli Lilly to buy three small vaccine developers
- Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO
- London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’